$XERS News

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

Xeris Biopharma Files Patent Infringement Lawsuits Related To Its KEYEVIS Product In U.S. District Court In New Jersey

Why Xeris Biopharma Holdings (XERS) Is Up 5.8% After Raising 2026 Revenue Guidance And Retiring Debt

Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14

Full Transcript: Xeris Biopharma Holdings Q2 2026 Earnings Call

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Lundbeck approaches Xeris Biopharma over potential takeover, Bloomberg reports

Xeris Biopharma Reportedly Draws Takeover Interest — But Firm Says It’s ‘Not For Sale’

Lundbeck Is Said To Express Interest In Buying Xeris Biopharma, Bloomberg Reports

Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy - Slideshow

Leerink Partners Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $16

Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism

Xeris Biopharma To Host XP‑8121 Program Overview Detailing Phase 3 Study And Commercial Opportunity; Topline Results Expected In Late 2028; FDA Approval And Launch Anticipated In 2030

Xeris Announces Details for XP-8121 Program Overview Webinar

Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity

Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $12

Why Xeris Biopharma Holdings (XERS) Is Up 8.4% After Tightening 2026 Revenue Guidance And Advancing XP-8121

Xeris Biopharma Holdings (XERS) Posts Record Q2 Revenue, Is It Still A Bargain?